Drug interactions
Bosentan + Vincristine liposomal
Severity: Minor
Bosentan and Vincristine liposomal: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Bosentan is a CYP3A4 inducer and could reduce vincristine exposure, potentially lowering its antitumor effect. Evidence for a clinically relevant effect is lacking.
What this interaction means in plain words
Bosentan and Vincristine liposomal have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Why it happens
Bosentan induces CYP3A4, increasing vincristine metabolism.
What to do
Monitor oncologic response and neurotoxicity. No routine dose change is needed.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Bosentan and Vincristine liposomal, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Bosentan
- Bosentan + Cyclosporin Contraindicated
- Bosentan + Glibenclamide Contraindicated
- Bosentan + Glyburide-metformin Contraindicated
- Bosentan + Lonafarnib Contraindicated
- Bosentan + Sparsentan Contraindicated
- Artemether / lumefantrine + Bosentan Major
Frequently asked questions
Can I take Bosentan with Vincristine liposomal?
MediHelp rates the interaction as minor. Bosentan and Vincristine liposomal have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Bosentan is a CYP3A4 inducer and could reduce vincristine exposure, potentially lowering its antitumor effect. Evidence for a clinically relevant effect is lacking.
How serious is the interaction between Bosentan and Vincristine liposomal?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor oncologic response and neurotoxicity. No routine dose change is needed.
What other medicines interact with Bosentan?
MediHelp also lists interactions of Bosentan with, for example, Cyclosporin, Glibenclamide, Glyburide-metformin. The full list is on the Bosentan page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
